Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.46% | -28.91% | -21.85% | -13.20% | 7.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.85% | -28.51% | -16.46% | 6.24% | 22.90% |
| Operating Income | 49.85% | 28.51% | 16.46% | -6.24% | -22.90% |
| Income Before Tax | 50.34% | 27.31% | 15.32% | -7.16% | -22.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.34% | 27.31% | 15.32% | -7.16% | -22.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.34% | 27.31% | 15.32% | -7.16% | -22.44% |
| EBIT | 49.85% | 28.51% | 16.46% | -6.24% | -22.90% |
| EBITDA | 49.83% | 28.46% | 16.41% | -6.35% | -23.04% |
| EPS Basic | 79.58% | 61.05% | 42.14% | 12.05% | -14.26% |
| Normalized Basic EPS | 79.58% | 61.05% | 42.14% | 12.05% | -14.26% |
| EPS Diluted | 79.58% | 61.07% | 42.18% | 12.12% | -14.17% |
| Normalized Diluted EPS | 79.58% | 61.05% | 42.14% | 12.05% | -14.26% |
| Average Basic Shares Outstanding | 214.10% | 124.70% | 78.99% | 36.87% | 8.71% |
| Average Diluted Shares Outstanding | 214.10% | 124.70% | 78.99% | 36.87% | 8.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |